Triphenylmethylethylene

Triphenylmethylethylene
Clinical data
Other names	Methyltriphenylethylene; Triphenylpropene
Drug class	Nonsteroidal estrogen
Identifiers
	IUPAC name 1,1-diphenylprop-1-en-2-ylbenzene;
CAS Number	3677-70-1;
PubChem CID	4207747;
ChemSpider	3417659;
UNII	92DB2Q7TH8;
CompTox Dashboard (EPA)	DTXSID601337056 ;
Chemical and physical data
Formula	C21H18
Molar mass	270.375 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(=C(C1=CC=CC=C1)C2=CC=CC=C2)C3=CC=CC=C3;
	InChI InChI=1S/C21H18/c1-17(18-11-5-2-6-12-18)21(19-13-7-3-8-14-19)20-15-9-4-10-16-20/h2-16H,1H3; Key:FLTIZNYOOOPPHQ-UHFFFAOYSA-N;

Triphenylmethylethylene, also known as methyltriphenylethylene or as triphenylpropene, is a synthetic nonsteroidal estrogen of the triphenylethylene group that is related to triphenylchloroethylene and was never marketed.^[1]^[2] Along with diethylstilbestrol and triphenylchoroethylene, triphenylmethylethylene was studied in 1944 by Sir Alexander Haddow for the treatment of breast cancer, and this is historically notable in that it was the first time that high-dose estrogens were found to be effective in the treatment of breast cancer.^[1]^[3] However, while diethylstilbestrol and triphenylchloroethylene were found to be significantly effective, triphenylmethylethylene was less effective and showed a favorable response in only 1 of 4 treated cases.^[4]^[5]

References

^ ^a ^b V. Craig Jordan (2013). Estrogen Action, Selective Estrogen Receptor Modulators, and Women's Health: Progress and Promise. World Scientific. pp. 42–43. ISBN 978-1-84816-958-6.
^ Hormones and Breast Cancer. Elsevier. 25 June 2013. pp. 9–. ISBN 978-0-12-416676-9.
^ D. J. Th. Wagener (13 July 2009). The History of Oncology. Bohn Stafleu van Loghum. pp. 189–. ISBN 978-90-313-6143-4.
^ Obiorah I, Jordan VC (2013). "Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality". Menopause. 20 (4): 372–82. doi:10.1097/GME.0b013e31828865a5. PMC 3740456. PMID 23921472. Of 4 cases of breast cancer treated with triphenylmethylethylene, only one showed a favorable response.
^ Sir James Hopwood Jeans (1928). The physics of the universe. Printed by R. & R. Clark, limited. p. 486. Triphenylmethylethylene was less effective than either stilbcestrol or triphenylchloroethylene.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

[Jordan2013-1] V. Craig Jordan (2013). Estrogen Action, Selective Estrogen Receptor Modulators, and Women's Health: Progress and Promise. World Scientific. pp. 42–43. ISBN 978-1-84816-958-6.

[Elsevier2013-2] Hormones and Breast Cancer. Elsevier. 25 June 2013. pp. 9–. ISBN 978-0-12-416676-9.

[Wagener2009-3] D. J. Th. Wagener (13 July 2009). The History of Oncology. Bohn Stafleu van Loghum. pp. 189–. ISBN 978-90-313-6143-4.

[pmid23921472-4] Obiorah I, Jordan VC (2013). "Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality". Menopause. 20 (4): 372–82. doi:10.1097/GME.0b013e31828865a5. PMC 3740456. PMID 23921472. Of 4 cases of breast cancer treated with triphenylmethylethylene, only one showed a favorable response.

[Jeans1928-5] Sir James Hopwood Jeans (1928). The physics of the universe. Printed by R. & R. Clark, limited. p. 486. Triphenylmethylethylene was less effective than either stilbcestrol or triphenylchloroethylene.

[1]

[2]

[3]

[4]

[5]

See also

References